HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Jones, A.M. Articles by Webb, A.K. Search for Related Content PubMed PubMed Citation Articles by Jones, A.M. Articles by Webb, A.K.

Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa

¹ Manchester Adult Cystic Fibrosis Centre, South Manchester University Hospitals NHS Trust, Manchester, ² School of Pharmacy, Queen's University, Belfast, and ³ Northern Ireland Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK

CORRESPONDENCE: A.M. Jones, Manchester Adult Cystic Fibrosis Centre, South Manchester University Hospitals NHS Trust, Southmoor Road, Manchester, M23 9LT, UK. Fax: 44 1612912080. E-mail: andmarkj@hotmail.com

Keywords: cross-infection, cystic fibrosis, inflammation, Pseudomonas aeruginosa

Received: January 14, 2003
Accepted May 8, 2003

Chronic Pseudomonas aeruginosa infection in cystic fibrosis (CF) leads to a damaging host inflammatory response. There are an increasing number of reports of P. aeruginosa cross-infection at CF centres. The clinical significance of acquisition of a transmissible strain for patients who already harbour P. aeruginosa is unclear. In this study, levels of inflammatory markers in clinically stable adult CF patients who harbour transmissible and sporadic strains of P. aeruginosa have been compared.

Patients with CF and chronic P. aeruginosa infection were grouped into those who harbour a transmissible P. aeruginosa and those who harbour their own sporadic strains. Total white cell and differential counts, sputum neutrophil elastase (NE), interleukin (IL)-8, tumour necrosis factor (TNF)-, plasma IL-6 and NE/₁-antitrypsin complexes, serum C-reactive protein, and urine TNF receptor 1 were all measured in clinically stable patients 4–6 weeks following completion of intravenous antibiotic therapy.

The two groups (both n=20) were well matched for per cent predicted forced expiratory volume in one second, per cent predicted forced vital capacity and body mass index. There were no significant differences in levels of white cell counts or inflammatory markers between the two groups.

At times of clinical stability, cystic fibrosis patients infected with transmissible Pseudomonas aeruginosa do not have a heightened inflammatory response above that of those harbouring sporadic strains.

This article has been cited by other articles:

				J S Elborn Practical Management of Cystic Fibrosis Chronic Respiratory Disease, July 1, 2006; 3(3): 161 - 165. [PDF]

				B. P. O'Sullivan and A. D. Michelson The Inflammatory Role of Platelets in Cystic Fibrosis Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 483 - 490. [Abstract] [Full Text] [PDF]

				D. Chambers, F. Scott, R. Bangur, R. Davies, A. Lim, S. Walters, G. Smith, T. Pitt, D. Stableforth, and D. Honeybourne Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis Eur. Respir. J., October 1, 2005; 26(4): 651 - 656. [Abstract] [Full Text] [PDF]

				K.W. Southern and P.M. Barker Azithromycin for cystic fibrosis Eur. Respir. J., November 1, 2004; 24(5): 834 - 838. [Abstract] [Full Text] [PDF]

				D.W. Reid, A. Champion, R. Bradbury, and S.M. Kirov Host response to transmissible Pseudomonas aeruginosa Eur. Respir. J., March 1, 2004; 23(3): 493 - 494. [Full Text] [PDF]